Subject Matter Experts
Andy Ajello is an accomplished commercial leader within the life science industry and has extensive experience in successfully leading the commercial efforts of new and existing products. He has hands on experience building best in class commercial capabilities and has led the launch and acceleration of multiple blockbuster products.
For the past 9 years, Andy served as the SVP of National Diabetes & Obesity Sales for Novo Nordisk. He was a member of the U.S. Executive Team, Global Management Board in Denmark, and the U.S. Pricing Committee that established payer and pricing strategy.
As a leader, he is described as authentic, visionary, engaging, inspirational and a developer of individuals and teams. He has been widely recognized for developing and motivating high-performing sales teams. In 2008 and in 2010 respectively, Andy was recognized in The Wall Street Journal and Investor’s Business Daily for his work managing the generational mix. Andy excels in fast paced, entrepreneurial and competitive environments where he can leverage his broad experience to set strategy and drive performance.
Andy is a graduate of Susquehanna University with a BA in Economics and resides in Princeton, NJ with his wife and two daughters.
Mark is a veteran SaaS revenue leader and has been leading revenue and sales teams and driving performance for the last 30 years in software and services companies. A results-oriented professional with a proven track record of delivering superior revenue results, Mark is passionate about scaling revenue organizations while helping customers to achieve their goals.
In his most recent role at MINDBODY, Mark held the role of Chief Revenue officer leading a global team that included the sales, services, and business development components of the business. Mark held senior roles at ADP, Citrix, Monster. Mark also helped SaaS startup organizations with their go to market strategy as part of his own consulting practice.
Mark received his BA in Business with an emphasis in marketing from Portland State University.
Outside of work, Mark enjoys the outdoors, running, biking, golfing, traveling and spending time with his wife and daughter where they reside in the Pacific Northwest.
Mark Devlin is a senior commercial leader in the biopharmaceutical arena who drives revenue growth. He is highly skilled in designing pricing and contracting strategies that deliver unfettered portfolio market access with Commercial and Government payors. His proficiency spans all payor channels and he has a track record of success in sales, marketing and market access across a diverse set of therapeutic areas.
Mark most recently was Senior Vice President, Managed Markets at Allergan PLC, a global pharmaceutical company with revenues of approximately $16B. He led a team of 130 people, served on executive steering committees and reported directly to the Chief Commercial Officer. In this role Mark led the portfolio pricing and market access strategies for a $12B U.S. pharmaceutical portfolio of approximately 40 brands in seven therapeutic markets. In addition to market access, Mark was responsible for Trade sales, distribution and customer service with all wholesale and retail customers. He managed the largest portfolio of contracted products on major PBM and health plan formularies and achieved a brand portfolio average of over 73% unrestricted access at discount rates below industry average. He also created and led a $500M annual patient co-pay support program for over three dozen brands that resulted in a Rx fulfillment rate over 82% and surpassing industry average. At the end of 2017, he negotiated new wholesaler distribution agreements that will save Allergan $60M over three years through fee reductions at all major U.S. drug wholesalers.
From 2007 – 2014, Mark was Senior Vice President, Managed Markets, Government and Policy at Forest Laboratories, where he developed corporate strategy and messaging on health care and public policy issues and led a team of 85 professionals in account management, contract operations, channel marketing, government affairs and public policy. In this role he launched a series of highly successful products, including Namenda XR in the commercial, Medicare and long-term care markets, and Bystolic, a branded beta-blocker in a heavily generic cardiovascular market. He also successfully managed the company’s federal lobbying initiative in support of the 2012 GAIN Act which resulted in an extra 5 years of market exclusivity for the company’s lead anti-infective product.
From 2002 – 2007, he was Vice President, Sales/Operations, where he spearheaded many successful product launches, co-led enterprise-wide technology deployments and designed multiple sales force incentive compensation programs. He also served on a corporate steering committee with co-promotion partner Sankyo Pharmaceuticals and was a founding member of the Forest Corporate Compliance Committee. Earlier in his career (1986 – 2002), Mark advanced through a series of increasingly responsible sales and operations roles in New England and New York.
Mark earned a Bachelor of Science in Biology with a minor in Chemistry at Fairleigh Dickinson University and attended the F.W. Olin Graduate School of Business at Babson College. He has continued his professional development with programs in strategic negotiation, executive leadership, group dynamics and other subjects through programs at Harvard University, Columbia University and the American Management Association.
MacKay Jimeson is an award winning public affairs and communications professional, a businessman and political adviser. As Managing Director of Ember Global Advisors, Jimeson helps position companies for growth in an evolving landscape of regulation, public opinion and disruptive competition. Previously, he led Corporate Affairs for Pfizer’s $9 billion Internal Medicine business. In that role he was responsible for public policy, government affairs, communications, advocacy and corporate responsibility for a portfolio of innovative medicines that prevent strokes, manage pain and treat tobacco addiction. Among Jimeson’s most notable accomplishments was his successful engagement strategy and message development that led to the unprecedented removal of an FDA Boxed Warning for the company’s smoking cessation medicine.
Previously, Jimeson was tapped by Pfizer’s Executive Vice President of Corporate Affairs, to serve as a special advisor where he developed an industry first digital grassroots initiative to support pro-medical innovation issues. He also served as Pfizer’s spokesperson and managed media relations. While in media relations he established strong relationships with global top-tier media, even earned praise from journalists themselves, and ultimately increasing the amount of favorable news coverage of Pfizer. Jimeson managed such complex company news as a spokesperson, such as the loss of exclusivity for the iconic cholesterol-lowering Lipitor when the patent expired.
Jimeson’s background in policy and public affairs were developed as an aide to Florida Governor Jeb Bush from 2001 to 2005. He served as a spokesman on education reform and recovery efforts after major hurricanes, wrote speeches and developed early digital campaigns. He was also an advisor on Senator John McCain’s 2008 presidential campaign.
Returning to his roots, Jimeson was active in Governor Bush’s 2016 presidential campaign, by serving as a policy advisor, on the national finance committee and by co-chairing Mission: NEXT, the largest Republican effort to engage millennial voters. He remains involved in politics and currently serves on the national finance committee for Texas Land Commissioner George P. Bush.
In 2016 PRWeek honored Jimeson by selecting him to their 40 under 40 list. The following year Maverick PAC, the premier national network for young conservative business professionals, named Jimeson to their list of the Future 40. In 2018 the American Council of Young Political Leaders, a program backed by the United States Department of State, selected Jimeson to serve on a seven person bipartisan delegation to Russia
Internationally recognized as a trusted advisor that accelerates business growth, Suzette possess a relentless drive to transform patient care, teamed with a keen ability to assess organizational opportunities, and assimilate ideas to drive financial success that align within a corporate culture. As an innovator, investor, thought leader, media contributor and sought after key note speaker/ educator on all things Specialty Pharmacy & Rare/Orphan Disease related; Suzette’s unique insight and savvy business advice continues to contribute to successful project executions and double digit revenue growth for Health Systems, Pharmaceutical/Biotech, Specialty Pharmacy and Private Equity/Venture Capital clients worldwide.
Suzette founded CSI Specialty Group In 2002, serving as President/CEO for 17 years. Under her leadership, honors include being named as one of Consulting Magazine’s Fastest Growing Firms, Goldman Sach’s Top Growing Businesses & recipient for an unprecedented 4 years in a row, of the coveted Commonwealth Institute’s Top 50 Women Led Business, from 2014-2018.
As a reflection of her dedication to the industry & servant leadership philosophy, Suzette received APPA’s Hall of Fame Award, honoring the ways she champions to improve patient care & access, as well as mentoring women through the Women in Specialty Pharmacy Organization she founded in 2013, and serving on the Executive team for the HBA Global Ambassador Program.
After a successful exit from CSI in 2019, Suzette seeks to guide innovative business models that have the opportunity to revolution and improve patient care outcomes, and may be seeking insight at the Board of Director, Advisory Board or Operating Partner level. She is also available for Consulting Projects and Subject Matter Expertise. A Proud West Point and Army mom, Suzette and her husband call Tampa, FL home.
Dan Duhart is a veteran commercial leader with 20+ years of strategic experience designing, building & managing commercial platforms. In his most recent role, Chief Commercial Officer, Dan headed up US/Global Commercial Operations for a US based medical device company where he was responsible for commercial strategy and execution across manufacturing, specialty distribution & HUB services through managed care access, marketing and sales execution.
Dan has worked for large pharmaceutical, small biotech, medical device companies across numerous therapeutic areas in both US, UK and EU markets. In addition, Dan has unique experience serving clients across healthcare systems supporting design and development of start-up commercial platforms while managing business development for Publicis Health, Touchpoint Solutions division.
Dan received his Bachelor of Science in Business Administration with emphasis in Finance, California State University, Northridge.
John P. Hall is a clinical development executive with 15+ years of industry experience. He began his career with a niche clinical research organization working through various operational departments before transitioning to the U.S. subsidiary of a Japanese pharmaceutical. He has been involved in all aspects of clinical trials from feasibility studies to archiving, Phase 1 (First in Human) to Phase 4 (Real World Evidence).
John started Shore Research & Development, LLC in 2012, a clinical operations consultancy focused on early clinical development. Shore R&D provides consultancy services for small to medium size biotechnology companies. Clients have been both private and public, primarily U.S. based but also included clients in South Korea and Belgium.
Over the past several years John has worked with clients to identify gaps in trial project management. John has successfully maximized the RFP process for trial services which has yielded costs savings and ensures vendor timeline accountability.
John is on the editorial board for Clinical Leader and on Gerson Lehrman Group Council of advisors. He received his BS from the University of Rhode Island and his MBA from Rider University. John is an avid runner and surfer and started Fund for 51 in 2011 to raise money for Duchenne Muscular Dystrophy.
John and his wife live in Spring Lake Heights, NJ and have 4 children.
Jim Hendrix is a recognized leader in health care analytics, with 20 years of experience with turning data into actionable intelligence. Most recently, Jim was VP, Methodology and Analytics at Symphony Health Solutions, where he had the lead role in developing and implementing the most effective analytic techniques for Symphony’s health care data.
Jim works with major industry players across all therapeutic areas, guiding them through analytics for patient treatment, prescriber patterns, and media impacts on patient and physician behavior. Jim specializes in helping clients to realize meaningful results, to distinguish key insights from interesting facts, and to optimize data acquisition and analysis.
Jim lives in Phoenix, Arizona with his wife Deborah and three children.
Irene Infanti, R.N., MSN
Ms. Infanti is an independent healthcare consultant with a focus on the pharmaceutical industry. Her career has spanned over thirty years in the areas of drug safety, medical information, customer contact center management, and patient assistance program management. Ms. Infanti’s most recent position was Director, Medical Information Center for Janssen Pharmaceuticals, a member of the Johnson & Johnson Family of Companies. She has extensive experience in customer relationship management, development and oversight of non-profit foundations, contracting with customer facing service providers, and ensuring compliance with federal regulations.
Prior to joining Johnson & Johnson, Ms. Infanti practiced as a clinical registered nurse at Johns Hopkins Hospital. She earned a Master Degree in Nursing Administration and Management from LaSalle University and a Bachelor Degree in Nursing from Niagara University. Ms. Infanti also holds a US Healthcare Compliance Certificate from Seton Hall University.
Bill Lowe is a seasoned commercial leader with over 30 years of experience in Consumer Goods. He has a proven track record of success in business turnaround operations and is known for using his cross functional knowledge/skills to solve complex organizational challenges. Bill has direct experience in Field Sales, National Account Leadership, Headquarter Sales & Operations, Marketing, Marketing Operations, Strategic Planning, Demand Planning, IT Project Delivery, Process Reengineering, Post Merger Integration, and Acquisition Due Diligence.
Most recently Bill was the National Sales Head for the Equity Star Portfolio & the Head of Sales Operations for all Business Units at Bayer Consumer Health. Bill was successful in developing a new go-to-market strategy for the Equity Star business unit and was successful in reversing a 5-year decline in sales and was the only business unit in the Division to achieve its’ top and bottom line commitments. Additionally, he built across all Business Units a new Sales Operations platform out of disparate functions that dramatically increased customer satisfaction.
Bill’s prior assignment was Senior Vice President of Commercial and Marketing Operations at Bayer, a platform that he built from ground up to enable all Business Units for competitive advantage. Functions included HCP Marketing, Business Planning, Demand Planning, Market Research, Media Strategy & Buying, Consumer Engagement, Business Analytics, and Division Initiatives.
Bill graduated Summa Cum Laude with a master’s in business administration from the University of Texas at Dallas. Undergraduate degree is a Bachelor of Science in Operations Management from the University of Tennessee. Bill lives in Mendham, New Jersey with his wife, Lisa, and 3 children.
Bill O’Donnell is an accomplished strategic, operational and financial executive with more than three decades of experience.
Over the past several years Bill teamed with a Private Equity Group and built a progressive healthcare communication company through a series of strategic acquisitions and integration of healthcare advertising, PR and digital companies. The company was built to serve clients across the healthcare ecosystem to include payers, providers, healthcare tech as well as drug and device manufactures.
Previously, Bill was the President and COO of inVentiv Health Communications. With over 2,000 employees, Bill led one of the largest healthcare communications companies worldwide. inVentiv worked with global pharma, biotech, medical device and diagnostic companies. inVentiv brought industry leading advertising, PR, medical education, digital, and media together for integrated solutions to accelerate performance for client’s brands.
Bill began his career in the banking industry in both financial and operational roles at Bank One, now JP Morgan Chase. Over his career, Bill forged long lasting relationships between his organizations and his clients built on trust, transparency and the attainment mutual of goals.
Bill and his wife live in Columbus, OH and have 4 children.
Ken Taylor is an accomplished agency executive with more than 25 years of success across the media, advertising and healthcare technology industries. Ken spent seven years as President at leading media agency, Starcom Worldwide. Most recently, Ken was a Managing Director at health tech start-up, Outcome Health.
Ken has partnered with numerous Fortune 500 companies as well as emerging brands to lead and transform their media practices. He has worked with the country’s largest and most successful marketers in developing media capabilities and building marketplace partnerships.
Through his extensive background in media, he has a depth of experience in areas critical to today’s marketers including media strategy, consumer behavior, digital transformation, data, analytics and investment stewardship.
Ken lives in Elmhurst, IL with his wife and two children.